Canabo Medical (CMM.V) is new to the Canadian markets, but it’s making waves in terms of its business plan, which is anything but typical.
Running a chain of ten cannabis referral clinics, staffed by doctors, who only see patients with genuine medical marijuana needs, the company makes revenue the same way any doctor’s clinic does – with consultation fees charged back to provincial health departments.
It doesn’t get a commission for sending patients to an LP. Because doctor’s aren’t supposed to do that.
But it does get a whole load of private health data sent on by the referring physicians, which it can then utilize (with the patient’s okay) to get a gigantic and detailed look at trends in the industry, what strains are most effective for what symptoms and demographics, what dosages are working out, and where patients are going for their medicine.
That information is not found anywhere else. And the ‘big data’ side of Canabo is one that could help every corner of the legal cannabis industry going forward.
For Stockhouse, I talked to Canabo Director Dr. Neil Smith about the finer details, and why recreational smokers aren’t helpful to their business model. Listen in and enjoy.
— Chris Parry
FULL DISCLOSURE: Canabo is an Equity.Guru marketing client, and the author/host owns stock in the company.
Hey Chris,
FYI – ALL the referring clinics DO receive funding from LPs. LPs provide the clinics a nominal payment of typically $25/month ($20-40) for each active client. The payment is ostensibly for research feedback from all that data you referred to above.
The company says openly that some LPs subscribe for access to their data. But they don’t take referral cash for where the patients shop. That’s the big conflict that doctors aren’t supposed to embrace.